Buy Alert: These 3 Coronavirus Stocks Are Heading Higher

On October 6, the European Medical Agency (EMA) announced the start of its expedited regulatory process for Pfizer (NYSE: PFE) and BioNTechs (NASDAQ: BNTX) Messenger RNA COVID-19 vaccine candidate BNT162b2. The experimental vaccine is currently in Phase 3 trials, with more than 28,000 out of 37,000 participants having completed their final dose. In Phase 1/2 testing and preclinical studies, participants taking BNT162b2 developed neutralizing antibodies, which are small proteins that recognize certain components of a pathogen and prevent it from entering healthy cells.

You should check here to buy the best price guaranteed products.

Last News

Olivia Culpo’s Baby Doll Dress & Shearling Slides Are a Cozy & Chic Alternative to Sweats for a Night In

‘Tsunami’ of violence erupts, DeSantis pursues school rules over race, and cruise titans tiptoe around law

Taiwan says will be 'force for good' after unprecedented G7 support

Hundreds of Israelis celebrate Netanyahu's unseating

South Dakota rocked again as a wind turbine plant shuts its doors

Joe Biden Agrees U.S.-Russia Relations “At A Low Point,” Defends Decision To Forgo Joint Press Conference With Vladimir Putin